Notice: This company has been marked as potentially delisted and may not be actively trading. (ANTX) (ANTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesTrendsBuy This Stock ANTX vs. TELO, GNLX, NLTX, ENTA, SGMT, MCRB, MGNX, VIRI, RENB, and TLSAShould you be buying (ANTX) stock or one of its competitors? The main competitors of (ANTX) include Telomir Pharmaceuticals (TELO), Genelux (GNLX), Neoleukin Therapeutics (NLTX), Enanta Pharmaceuticals (ENTA), Sagimet Biosciences (SGMT), Seres Therapeutics (MCRB), MacroGenics (MGNX), Virios Therapeutics (VIRI), Renovaro (RENB), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical preparations" industry. (ANTX) vs. Telomir Pharmaceuticals Genelux Neoleukin Therapeutics Enanta Pharmaceuticals Sagimet Biosciences Seres Therapeutics MacroGenics Virios Therapeutics Renovaro Tiziana Life Sciences (ANTX) (NYSE:ANTX) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Do institutionals and insiders hold more shares of ANTX or TELO? 90.5% of (ANTX) shares are held by institutional investors. 20.8% of (ANTX) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ANTX or TELO more profitable? (ANTX)'s return on equity of -57.62% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets (ANTX)N/A -57.62% -52.08% Telomir Pharmaceuticals N/A -1,170.58%-832.67% Does the MarketBeat Community favor ANTX or TELO? (ANTX) received 94 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Telomir Pharmaceuticals an outperform vote while only 58.54% of users gave (ANTX) an outperform vote. CompanyUnderperformOutperform(ANTX)Outperform Votes9658.54% Underperform Votes6841.46% Telomir PharmaceuticalsOutperform Votes2100.00% Underperform VotesNo Votes Do analysts rate ANTX or TELO? (ANTX) currently has a consensus target price of $2.67, indicating a potential upside of 91.16%. Telomir Pharmaceuticals has a consensus target price of $15.00, indicating a potential upside of 279.75%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telomir Pharmaceuticals is more favorable than (ANTX).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score (ANTX) 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has stronger valuation & earnings, ANTX or TELO? Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than (ANTX), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio(ANTX)N/AN/A-$64.73M-$2.04-0.68Telomir PharmaceuticalsN/AN/A-$16.53M-$0.58-6.81 Does the media refer more to ANTX or TELO? In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than (ANTX). MarketBeat recorded 2 mentions for Telomir Pharmaceuticals and 1 mentions for (ANTX). Telomir Pharmaceuticals' average media sentiment score of 0.93 beat (ANTX)'s score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment (ANTX) 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTelomir Pharmaceuticals beats (ANTX) on 8 of the 14 factors compared between the two stocks. Remove Ads Get (ANTX) News Delivered to You Automatically Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANTX vs. The Competition Export to ExcelMetric(ANTX)Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$33.76M$6.91B$5.63B$19.37BDividend YieldN/A2.79%5.33%3.76%P/E Ratio-0.687.2623.6233.06Price / SalesN/A218.91384.7226.59Price / CashN/A65.6738.1717.55Price / Book0.336.386.894.53Net Income-$64.73M$142.34M$3.20B$1.02B (ANTX) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANTX(ANTX)2.3163 of 5 stars$1.40+14.3%$2.67+91.2%-57.1%$33.76MN/A-0.68N/AAnalyst RevisionTELOTelomir Pharmaceuticals2.3566 of 5 stars$4.53-0.7%$15.00+231.1%-23.3%$134.83MN/A-7.811Gap DownGNLXGenelux1.2596 of 5 stars$3.89-1.0%$18.25+369.2%-52.1%$134.35M$8,000.00-4.0910Earnings ReportUpcoming EarningsAnalyst RevisionNLTXNeoleukin TherapeuticsN/A$14.21-6.7%N/A-71.5%$133.55MN/A-4.5790High Trading VolumeENTAEnanta Pharmaceuticals3.9632 of 5 stars$6.20-1.7%$17.25+178.2%-67.3%$132.27M$66.59M-1.25160SGMTSagimet Biosciences2.8777 of 5 stars$4.13+3.5%$23.00+456.9%-31.5%$126.69M$2M-2.898Short Interest ↓Gap UpMCRBSeres Therapeutics3.4664 of 5 stars$0.71+0.3%$4.00+460.9%-6.9%$124.34M$126.33M-3.10330Positive NewsMGNXMacroGenics3.8898 of 5 stars$1.96-1.8%$7.63+289.0%-91.4%$123.02M$148.34M-1.24430VIRIVirios Therapeutics0.3922 of 5 stars$6.33-7.3%$3.00-52.6%+1,077.2%$121.90MN/A-23.445Gap UpRENBRenovaro1.059 of 5 stars$0.72+2.6%N/A-78.1%$114.04MN/A-0.7720Positive NewsGap DownTLSATiziana Life Sciences0.4849 of 5 stars$1.08-2.7%N/A+146.7%$113.83MN/A0.008Short Interest ↑Gap Up Remove Ads Related Companies and Tools Related Companies TELO Competitors GNLX Competitors NLTX Competitors ENTA Competitors SGMT Competitors MCRB Competitors MGNX Competitors VIRI Competitors RENB Competitors TLSA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANTX) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ANTX) Please log in to your account or sign up in order to add this asset to your watchlist. Share (ANTX) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANTX Stock Free ANTX Stock Alerts